Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

ADDING and REPLACING European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older

December 15, 2021

From Merck & Co., Inc.

Via Business Wire

European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older

December 15, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Issues $1 Billion Inaugural Sustainability Bond

December 13, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection

December 13, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Prices $8.0 Billion Debt Offering

December 07, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities

December 07, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection

December 06, 2021

From Merck & Co., Inc.

Via Business Wire

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection

December 03, 2021

From Merck & Co., Inc.

Via Business Wire

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children

December 01, 2021

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults

November 30, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Announces First-Quarter 2022 Dividend

November 30, 2021

From Merck & Co., Inc.

Via Business Wire

Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma

November 30, 2021

From Merck & Co., Inc.

Via Business Wire

FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review

November 30, 2021

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma

November 29, 2021

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

November 29, 2021

From Merck & Co., Inc.

Via Business Wire

Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference

November 24, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Completes Acquisition of Acceleron Pharma Inc.

November 22, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.

November 19, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1

November 18, 2021

From Merck & Co., Inc.

Via Business Wire

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

November 18, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.

November 17, 2021

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting

November 17, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event

November 11, 2021

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval

November 10, 2021

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

November 09, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.

November 08, 2021

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World

November 04, 2021

From Merck & Co., Inc.

Via Business Wire

New Research for KEYTRUDA® (pembrolizumab) at Society for Melanoma Research (SMR) 2021 Congress Reinforces Merck’s Commitment to Patients With Melanoma Across Stages of Disease

October 31, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.

October 29, 2021

From Merck & Co., Inc.

Via Business Wire

Merck Announces Third-Quarter 2021 Financial Results

October 28, 2021

From Merck & Co., Inc.

Via Business Wire

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Merck & Co., Inc.

Starting at /week.